Ellagic acid protects against cisplatin-induced nephrotoxicity in rats: A dose-dependent study

N. Al-Kharusi, H. A. Babiker, S. Al-Salam, M. I. Waly*, A. Nemmar, I. Al-Lawati, J. Yasin, S. Beegam, B. H. Ali

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)


BACKGROUND: The anticancer-drug cisplatin (CP) causes nephrotoxicity through different mechanisms, including generation of free radicals. Ellagic acid (EA) is a polyphenolic antioxidant found in fruits and nuts. AIM: This study aimed to investigate the ability of different doses of EA to ameliorate CP nephrotoxicity in rats. MATERIALS AND METHODS: Animals were randomly divided into six groups and treated with saline; CP alone (6 mg/kg); two doses of EA, both alone (10 and 30 mg/kg) or with CP. RESULTS: Treatment with CP alone reduced body weight, water intake, urine output, and renal total antioxidant and reduced glutathione (GSH) concentrations (p <0.01). In addition, it increased relative kidney weight, plasma creatinine, and blood urea nitrogen (BUN) concentrations (p <0.01). However, a dose of 30 mg/kg EA mitigated most of the CP-induced actions, but no effect was seen for the 10 mg/kg dose. Histopathologically, rats given CP+EA30 showed <25% necrotic lesions in the renal cortical area compared with

Original languageEnglish
Pages (from-to)299-310
Number of pages12
JournalEuropean Review for Medical and Pharmacological Sciences
Issue number3
Publication statusPublished - 2013


  • Cisplatin
  • Ellagic acid
  • Nephrotoxicity
  • Rats

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)


Dive into the research topics of 'Ellagic acid protects against cisplatin-induced nephrotoxicity in rats: A dose-dependent study'. Together they form a unique fingerprint.

Cite this